CONTACT US: Contact info
|
Citation |
Chisholm D, Van Ommeren M, Ayuso-Mateos JL, Saxena S. Br. J. Psychiatry 2005; 187: 559-567. |
|
Affiliation |
Department of Health System Financing, Evidence and Information for Policy (EIP), World Health Organization, 1211 Geneva, Switzerland. ChisholmD@who.int |
|
Copyright |
(Copyright © 2005, Royal College of Psychiatry) |
|
DOI |
|
PMID |
16319409 |
|
Abstract |
BACKGROUND: Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden. AIMS: To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder. METHOD: Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios. RESULTS: Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions). CONCLUSIONS: Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income. Language: en |